A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients… Read More ›
I’d like to talk about contemporary researchers’ rigid and limited approach to combination therapy. This is the model whose many limitations I point out with the ridiculously long label “mini-T3-mono-combination” therapy. I’ll go over some of the history behind this… Read More ›
Most studies of Low T3 syndrome (NTIS) routinely EXCLUDE thyroid patients. Sadly, our exclusion has become a research tradition. In this post, I lay out the landscape and extent of our exclusion from this valuable area of thyroid hormone health… Read More ›
Clinical trials of T3 (Liothyronine) have been barking up the wrong tree. The limitations of their research designs are now actively harming patients who need T3 medication. Prices for T3 have been rising, medical prejudice against T3 is rising, worldwide… Read More ›
Why have clinical trials of T3-T4 combination therapy failed to show significant benefit? Hoermann et al explain that the trials and the meta-analyses exhibit a fundamental problem with research methodology and a fundamental misunderstanding of thyroid hormone relationships that results… Read More ›
Research Review Carlé A, Faber J, Steffensen R, Laurberg P, Nygaard B. Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment – Data Using a Blind, Randomized, Clinical Study. Eur Thyroid J. 2017;6(3):143-151…. Read More ›